Table 1.
List of the neurologic manifestations in the current COVID-19 pandemic.
| Neurologic manifestation |
Patient numbers (% in total participants) |
Total participants |
Age: mean [SD] or median [IQR] |
Published journal reference |
|---|---|---|---|---|
| With olfactory or/and taste disorders | 20 (33.9%) | 59 | 60 [50–74] | Clin Infect Dis (8) |
| 53 (12.4%) | 429 | 32 [4–88] | Taiwan CDC (9) | |
| 128 (75.7) | 169 | 43 [34–54] | Int Forum Allergy Rhinol (10) | |
| 25 (20%) | 126 | 43.5 [3–87] | Trav Med Infect Dis (11) | |
| 62 (19.4%) | 320 | No data | Laryngoscope (12) | |
| 31 (39.2%) | 79 | 61.6 [17.4] | Eur J Neurol (13) | |
| 130 (64.4%) | 202 | 56 [45–67] | JAMA (14) | |
| 1 | Case report | 80 | Eur J Case Rep Intern Med (15) | |
| 1 | Case report | 50 | Neurology (16) | |
| Olfactory disorder only | 3 (5.1%) | 59 | 60 [50–74] | Clin Infect Dis (8) |
| 11 (5.1%) | 214 | 52.7 [15.5] | JAMA Neurol (2) | |
| 357 (85.6%) | 417 | 36.9 [11.4] | EUR ARCH OTO-RHINO-L (17) | |
| 1 | Case report | 85 | Eur J Case Rep Intern Med (15) | |
| Taste disorder only | 5 (8.5%) | 59 | 60 [50–74] | Clin Infect Dis (8) |
| 12 (5.6%) | 214 | 52.7 [15.5] | JAMA Neurol (2) | |
| 342 (82%) | 417 | 36.9 [11.4] | EUR ARCH OTO-RHINO-L (17) | |
| 1 | Case report | 39 | Neurology (16) | |
| Dizziness | 1 (12.5%) | 8 | 48.1 [13–76] | Clin Infect Dis (18) |
| 13 (9.4%) | 138 | 56 [42–68] | JAMA (19) | |
| 37 (8.1%) | 452 | 58 [47–67] | Clin Infect Dis (20) | |
| 21 (8%) | 274 | 62 [44–70] | BMJ (21) | |
| 5 (7%) | 69 | 42 [35–62] | Clin Infect Dis (22) | |
| 1 (4.17%) | 24 | 32.5 [5–95] | Sci China Life Sci (23) | |
| 2 (2%) | 81 | 49.5 [11] | Lancet (24) | |
| Altered mental status | 9 (52.9%) | 17 | 86.5 [68.6–97.] | J Infect (25) |
| 9 (9%) | 99 | 55.5 [21–88] | Lancet (26) | |
| 1 (5.9%) | 17 | 75 [48–89] | J Med Virol (27) | |
| 3 (0.7%) | 452 | 58 [47–67] | Clin Infect Dis (20) | |
| 1 | Case report | No data | Radiology (28) | |
| 1 | Case report | 74 | J Med Virol (29) | |
| Seizure | 1 (4.8%) | 21 | 70 [43–92] | JAMA (30) |
| 1 (0.5%) | 214 | 52.7 [15.5] | JAMA Neurol (2) | |
| Acute cerebrovascular disease | 3 (23%) | 13 | 63 | N Engl J Med (31) |
| 6 (2.8) | 214 | 52.7 [15.5] | JAMA Neurol (2) | |
| 5 | No data | 40.4 [5.6] | N Engl J Med (32) | |
| Neuralgia | 5 (2.3%) | 214 | 52.7 [15.5] | JAMA Neurol (2) |
| Ataxia | 1 (0.5%) | 214 | 52.7 [15.5] | JAMA Neurol (2) |
| Guillain-Barre syndrome | 5 (0.4%) | 1,000–1,200 | No data | N Engl J Med (33) |
| 1 | Case report | 61 | Lancet Neurol (34) | |
| 1 | Case report | 65 | J Clin Neurosci (35) | |
| 1 | Case report | 71 | Neurol Neuroimmunol Neuroinflamm (36) |
|
| Encephalitis | 1 | Case report | 24 | Int J Infect Dis (37) |
| 1 | Case report | 56 | Travel Med Infect Dis (38) | |
| 1 | Case report | 74 | Cureus (39) | |
| 1 | Case report | No data | Brain Behav Immun (40) | |
| 1 | Case report | 41 | Brain Behav Immun (41) | |
| Intracerebral hemorrhage | 1 | Case report | 79 | New Microbes New Infect (42) |
| Miller Fisher Syndrome | 1 | Case report | 50 | Neurology (16) |
| Polyneuritis cranialis | 1 | Case report | 39 | Neurology (16) |
| Sustained upward gaze, dystonic bilateral leg extension and altered responsiveness | 1 | Case report | 6 week | Neurology (43) |